CD38 Human shRNA Lentiviral Particle (Locus ID 952)

CAT#: TL314088V

CD38 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL314088A virus into HEK293 cells. TL314088A virus was prepared using lenti-shRNA TL314088A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL314088B virus into HEK293 cells. TL314088B virus was prepared using lenti-shRNA TL314088B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL314088C] virus into HEK293 cells. [TL314088C] virus was prepared using lenti-shRNA [TL314088C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL314088D] virus into HEK293 cells. [TL314088D] virus was prepared using lenti-shRNA [TL314088D] and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 952
• Synonyms: ADPRC 1; ADPRC1
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_001775, NR_132660, NM_001775.1, NM_001775.2, NM_001775.3, BC007964, BC007964.2, NM_001775.4
• UniProt ID: P28907
• Summary: The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).